The U.S. Food and Drug Administration (FDA) has officially approved lenacapavir, a groundbreaking drug for HIV Drug prevention, rooted in decades of research by University of Utah biochemist Wesley Sundquist. This medication, marketed under the name Yeztugo, was developed by Gilead Sciences and is already being hailed as a game-changer in the fight against HIV. Lenacapavir is designed to HIV Drug by targeting the virus’s protein shell—known as the capsid—essentially halting its ability to replicate. Sundquist’s laboratory laid the foundational understanding of this protein structure back in the late 1990s. His team discovered how sensitive the virus’s shell is to small changes, revealing a new path for treatment. Gilead Sciences took note of these findings and eventually collaborated with Sundquist to create lenacapavir. Unlike many existing HIV medications, lenacapavir stands out for its long-lasting protection. Administered just twice a year, it offers a six-month shield against the virus. According to Sundquist, clinical trials have shown it to be “more potent than any drug available,” with remarkable efficacy and durability.